Products & Services · Total revenues
GIVLAARI — Total revenues
Alnylam Pharmaceuticals GIVLAARI — Total revenues decreased by 14.3% to $74.39M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11.1%, from $66.97M to $74.39M. Over 4 years (FY 2021 to FY 2025), GIVLAARI — Total revenues shows an upward trend with a 24.6% CAGR.
Analysis
Metric ID:
alny_segment_givlaari_total_revenuesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $30.63M | $31.83M | $40.68M | $35.28M | $45.15M | $45.66M | $47.06M | $47.91M | $57.9M | $54.15M | $59.3M | $58.06M | $62.13M | $71.04M | $64.65M | $66.97M | $80.85M | $73.87M | $86.8M | $74.39M |
| QoQ Change | — | +3.9% | +27.8% | -13.3% | +28.0% | +1.1% | +3.1% | +1.8% | +20.9% | -6.5% | +9.5% | -2.1% | +7.0% | +14.4% | -9.0% | +3.6% | +20.7% | -8.6% | +17.5% | -14.3% |
| YoY Change | — | — | — | — | +47.4% | +43.4% | +15.7% | +35.8% | +28.2% | +18.6% | +26.0% | +21.2% | +7.3% | +31.2% | +9.0% | +15.4% | +30.1% | +4.0% | +34.3% | +11.1% |
Range$30.63M – $86.8M
CAGR+20.5%
Avg YoY Growth+23.7%
Median YoY Growth+23.6%
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's givlaari — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported givlaari — total revenues of $74.39M in Q1 2026.
- How has Alnylam Pharmaceuticals's givlaari — total revenues changed year-over-year?
- Alnylam Pharmaceuticals's givlaari — total revenues increased by 11.1% year-over-year, from $66.97M to $74.39M.
- What is the long-term trend for Alnylam Pharmaceuticals's givlaari — total revenues?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's givlaari — total revenues has grown at a 24.6% compound annual growth rate (CAGR), from $127.82M to $308.49M.